CytoVac A/S is a biotechnology company that is developing a new method for treatment of cancer.


A treatment method that is based on the patient's own immune system. This treatment method is called ALECSAT therapy and is based on enabling the patient's own immune system to fight the cancer.

Applying the ALECSAT method, one can, from a blood donation from the patient, isolate, activate and cultivate specific cells from the immune system outside the patient’s body. These cells are then delivered back to cancer patient where they attack cancer cells and enhance the patient's immune system in the battle against cancer.

Good clinical data:

In the prostate cancer trials we are able to lower or stabilize Prostate Specific Antigen (PSA) levels (a validated indicator of prostate cancer development) and in the Glioblastoma trial preliminary data suggest that most patients either show stable disease or even slight tumor regressions after treatment with ALECSAT!Read more

 Partners


●    The Danish Cancer Society/ Kræftens Bekæmpelse
Cancergenetisk laboratorium, Strandboulevarden 49,
2100 København Ø., Danmark

●    Larix A/S, Clinical Research Organization (CRO),
Tempovej 44, 2750 Ballerup, Denmark.

●    Signifikans ApS, Datamanagement,
Rundforbivej 2, 2950 Vedbæk, Danmark

●    Læge Lars Tue Sørensen and Overlæge Dr. Med. Henrik Harling
Kirurgisk Afdeling K, Bispebjerg Hospital, Denmark.

●    Overlæge Aida Muhic
Department of Oncology, Rigshospitalet, Copenhagen University hospital, Danmark.

●    Overlæge Charlotte Aaquist Haslund
Department of Oncology, Aalborg University hospital, Denmark.

●    Slávka Lukacova, Reservelæge.
Department of Oncology, Århus University hospital, Denmark

CytoVac A/S


Scion DTU forskerparken

Venlighedsvej 6

DK 2970 Hørsholm

Denmark


Tlf: +45 45 57 22 45

Fax: +45 45 57 22 40

Email: info@cytovac.dk

Management and Board of Directors


CEO: Martin Roland Jensen M.Sc. Ph.D.

CSO: Dr. Alexei Kirkin MD.Ph.D.

Chairman of the Board: Jan Kuhlmann Andersen

Boardmember: Bent Alsø

Boardmember: Pia Wolff-Sneedorff

Boardmember: Jarne Elleholm

Boardmember: Jørgen K Kimø


CytoVac research and production facilities are located in the Scion-DTU Research Park at Hørsholm outside Copenhagen.

The dedicated GMP production facilities are approved by the Danish authorities for handling human cells and tissue.

Hjem

Read our Latest News

Logo CytoVac
Home Technology Clinical Management News About Us